The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Dot: Use at an assay dependent dilution.
ELISA: 1/4000 - 1/20000.
This product has been assayed against 1.0µg of Folate Binding Protein in a standard capture ELISA using Peroxidase conjugated streptavidin and ABTS (2,2'-azino-bis-[3-ethylbenthiazoline-6-sulfonic-acid]) as a substrate for 30 minutes at RT.
IM: Use at an assay dependent dilution.
WB: Use at an assay dependent dilution. Predicted molecular weight: 31 kDa.
Suitable for other antibody based assays using streptavidin or avidin conjugates.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Binds to folate and reduced folic acid derivatives and mediates delivery of 5-methyltetrahydrofolate to the interior of cells.
Exclusively expressed in tissues of epithelial origin. Expression is increased in malignant tissues. Expressed in kidney, lung and cerebellum.
Involvement in disease
Defects in FOLR1 are the cause of neurodegeneration due to cerebral folate transport deficiency (NCFTD) [MIM:613068]. NCFTD is an autosomal recessive disorder resulting from brain-specific folate deficiency early in life. Onset is apparent in late infancy with severe developmental regression, movement disturbances, epilepsy, and leukodystrophy. Note=Recognition and diagnosis of this disorder is critical because folinic acid therapy can reverse the clinical symptoms and improve brain abnormalities and function.
Belongs to the folate receptor family.
Eight disulfide bonds are present. The secreted form is derived from the membrane-bound form either by cleavage of the GPI anchor, or/and by proteolysis catalyzed by a metalloprotease.